Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2006 1
2007 2
2008 1
2009 1
2010 1
2011 2
2012 2
2013 1
2014 9
2015 18
2016 14
2017 18
2018 14
2019 6
2020 24
2021 22
2022 25
2023 15
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Results by year

Filters applied: . Clear all
Page 1
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE, Kataoka Y, Chu CY, DiBonaventura M, Rojo R, Antinew J, Ionita I, Sinclair R, Forman S, Zdybski J, Biswas P, Malhotra B, Zhang F, Valdez H; JADE COMPARE Investigators. Bieber T, et al. N Engl J Med. 2021 Mar 25;384(12):1101-1112. doi: 10.1056/NEJMoa2019380. N Engl J Med. 2021. PMID: 33761207 Clinical Trial.
Neonatal lupus erythematosus - practical guidelines.
Derdulska JM, Rudnicka L, Szykut-Badaczewska A, Mehrholz D, Nowicki RJ, Barańska-Rybak W, Wilkowska A. Derdulska JM, et al. Among authors: nowicki rj. J Perinat Med. 2021 Jan 18;49(5):529-538. doi: 10.1515/jpm-2020-0543. Print 2021 Jun 25. J Perinat Med. 2021. PMID: 33470961 Review.
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators. Simpson EL, et al. N Engl J Med. 2016 Dec 15;375(24):2335-2348. doi: 10.1056/NEJMoa1610020. Epub 2016 Sep 30. N Engl J Med. 2016. PMID: 27690741 Free article. Clinical Trial.
Genetic and Epigenetic Aspects of Atopic Dermatitis.
Nedoszytko B, Reszka E, Gutowska-Owsiak D, Trzeciak M, Lange M, Jarczak J, Niedoszytko M, Jablonska E, Romantowski J, Strapagiel D, Skokowski J, Siekierzycka A, Nowicki RJ, Dobrucki IT, Zaryczańska A, Kalinowski L. Nedoszytko B, et al. Among authors: nowicki rj. Int J Mol Sci. 2020 Sep 4;21(18):6484. doi: 10.3390/ijms21186484. Int J Mol Sci. 2020. PMID: 32899887 Free PMC article. Review.
Etiopathogenesis and Emerging Methods for Treatment of Vitiligo.
Iwanowski T, Kołkowski K, Nowicki RJ, Sokołowska-Wojdyło M. Iwanowski T, et al. Among authors: nowicki rj. Int J Mol Sci. 2023 Jun 5;24(11):9749. doi: 10.3390/ijms24119749. Int J Mol Sci. 2023. PMID: 37298700 Free PMC article. Review.
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S, Grattan C, Fomina D, Rigopoulos D, Berard F, Canonica GW, Rockmann H, Irani C, Szepietowski JC, Leflein J, Bernstein JA, Peter JG, Kulthanan K, Godse K, Ardusso L, Ukhanova O, Staubach P, Sinclair R, Gogate S, Thomsen SF, Tanus T, Ye YM, Burciu A, Barve A, Modi D, Scosyrev E, Hua E, Letzelter K, Varanasi V, Patekar M, Severin T; PEARL-1 and PEARL-2 trial investigators. Maurer M, et al. Lancet. 2024 Jan 13;403(10422):147-159. doi: 10.1016/S0140-6736(23)01684-7. Epub 2023 Nov 23. Lancet. 2024. PMID: 38008109 Clinical Trial.
Contact Dermatitis to Diabetes Medical Devices.
Cichoń M, Trzeciak M, Sokołowska-Wojdyło M, Nowicki RJ. Cichoń M, et al. Among authors: nowicki rj. Int J Mol Sci. 2023 Jun 27;24(13):10697. doi: 10.3390/ijms241310697. Int J Mol Sci. 2023. PMID: 37445875 Free PMC article. Review.
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Griffiths CE, et al. Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10. Lancet. 2015. PMID: 26072109 Clinical Trial.
Segmental neurofibromatosis.
Sobjanek M, Dobosz-Kawałko M, Michajłowski I, Pęksa R, Nowicki R. Sobjanek M, et al. Among authors: nowicki r. Postepy Dermatol Alergol. 2014 Dec;31(6):410-2. doi: 10.5114/pdia.2014.40942. Epub 2014 Dec 3. Postepy Dermatol Alergol. 2014. PMID: 25610358 Free PMC article.
166 results